Leerink Partners analyst David Risinger has maintained their bullish stance on ANAB stock, giving a Buy rating yesterday.
David Risinger has given his Buy rating due to a combination of factors related to AnaptysBio’s strategic collaborations and potential financial gains. The significant increase in sales of Jemperli, a product under AnaptysBio’s collaboration with GSK, indicates strong market performance and potential for future growth. AnaptysBio stands to benefit from a substantial milestone payment if Jemperli achieves a certain sales threshold, which seems increasingly likely given the current sales trajectory.
Additionally, the expansion of Jemperli’s market presence, including recent approvals in multiple countries, further supports the positive outlook. The upcoming clinical trial results for another collaborative project, cobolimab, could also serve as a catalyst for AnaptysBio’s stock. These factors combined suggest a promising financial future for AnaptysBio, justifying the Buy rating.
In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $40.00 price target.
ANAB’s price has also changed slightly for the past six months – from $22.180 to $22.220, which is a 0.18% increase.